Evidence map›Paper›PMID 20167860›Full record

ArticleThe American journal of pathology2010

Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer.

Adrian M Jubb, Elizabeth J Soilleux, Helen Turley, Graham Steers, Andrew Parker, Irene Low, Jennifer Blades, Ji-Liang Li, Paul Allen, Russell Leek and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Notch signaling regulates pulmonary fibrosis.Frontiers in cell and developmental biology · 2024
    Review
  10. Review
  11. Article
  12. Targeting adipocyte-immune cell crosstalk to control breast cancer progression.Journal of cancer research and clinical oncology · 2023
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Adrian M JubbNuffield Department of Clinical Laboratory Sciences,Weatherall Institute ofMolecular Medicine, University of Oxford, Oxford, UK.
Elizabeth J Soilleux
Helen Turley
Graham Steers
Andrew Parker
Irene Low
Jennifer Blades
Ji-Liang Li
Paul Allen
Russell Leek
Irene Noguera-Troise
Kevin C Gatter
Gavin Thurston
Adrian L Harris
University of Oxford · GBJohn Radcliffe Hospital · GBRegeneron (United States) · US

Funding

Cancer Research UK
6 · The paper itself

Abstract

Delta-like ligand 4 (Dll4) is a Notch ligand that is predominantly expressed in the endothelium. Evidence from xenografts suggests that inhibiting Dll4 may overcome resistance to antivascular endothelial growth factor therapy. The aims of this study were to characterize the expression of Dll4 in breast cancer and assess whether it is associated with inflammatory markers and prognosis. We examined 296 breast adenocarcinomas and 38 ductal carcinoma in situ tissues that were represented in tissue microarrays. Additional whole sections representing 10 breast adenocarcinomas, 10 normal breast tissues, and 16 angiosarcomas were included. Immunohistochemistry was then performed by using validated antibodies against Dll4, CD68, CD14, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), CD123, neutrophil elastase, CD31, and carbonic anhydrase 9. Dll4 was selectively expressed by intratumoral endothelial cells in 73% to 100% of breast adenocarcinomas, 18% of in situ ductal carcinomas, and all lactating breast cases, but not normal nonlactating breast. High intensity of endothelial Dll4 expression was a statistically significant adverse prognostic factor in univariate (P = 0.002 and P = 0.01) and multivariate analyses (P = 0.03 and P = 0.04) of overall survival and relapse-free survival, respectively. Among the inflammatory markers, only CD68 and DC-SIGN were significant prognostic factors in univariate (but not multivariate) analyses of overall survival (P = 0.01 and 0.002, respectively). In summary, Dll4 was expressed by endothelium associated with breast cancer cells. In these retrospective subset analyses, endothelial Dll4 expression was a statistically significant multivariate prognostic factor.

Indexed as

Adaptor Proteins, Signal TransducingAgedBreastBreast NeoplasmsCalcium-Binding ProteinsCell Line, TumorDisease-Free SurvivalEndotheliumFemaleHemangiosarcomaHumansImmunohistochemistryInflammationIn Situ HybridizationIntercellular Signaling Peptides and ProteinsMiddle AgedAdaptor Proteins, Signal TransducingCalcium-Binding ProteinsDLL4 protein, humanIntercellular Signaling Peptides and Proteins

Identifiers

PMID20167860
PMCPMC2843489
OpenAlexW2014016903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.